There are no patents, products in development or marketed products to declare. Eone Laboratories, Green Cross Laboratories, and Seoul Clinical Laboratories provided support in the form of salaries for authors GO, SL and AL, but did not have any additional role in the study design, data collection and analysis, decision of publish, or preparation of the manuscript.Ĭompeting interests: Gwi Young Oh is employed by Eone Laboratories, Sang Gon Lee by Green Cross Laboratories and Anna Lee by Seoul Clinical Laboratories. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedĭata Availability: All relevant data are within the paper.įunding: The authors received no specific funding for this work. Received: JAccepted: SeptemPublished: September 30, 2015Ĭopyright: © 2015 Moon et al. PLoS ONE 10(9):Įditor: Herman Tse, The University of Hong Kong, HONG KONG (2015) Evaluation of the Bio-Rad Geenius HIV 1/2 Confirmation Assay as an Alternative to Western Blot in the Korean Population: A Multi-Center Study. HIV-1 NAT should be performed in negative or indeterminate specimens by Geenius HIV1/2 to detect acute HIV infection as recommended in new HIV testing algorithms.Ĭitation: Moon H-W, Huh HJ, Oh GY, Lee SG, Lee A, Yun Y-M, et al. ![]() It has an excellent performance and can be a reliable alternative to WB. The Geenius HIV1/2 is simple and time-saving compared with WB. Agreement between Geenius HIV1/2 and WB was excellent (weighted Kappa = 0.89). When we considered only WB, the sensitivity and specificity of Geenius HIV1/2 were 100.0% and 99.1%, respectively. The sensitivity and specificity of Geenius HIV1/2 were 95.3% and 100.0%, respectively. Among 58 negative or indeterminate specimens by Geenius HIV1/2, four specimens (6.9%) were positive by HIV-1 NAT. ![]() Among 140 reactive specimens by HIV Ag/Ab assay, 82 (58.6%) were positive for HIV-1 Ab by Geenius HIV1/2. ![]() HIV-1 nucleic acid amplification test (NAT) was performed in negative or indeterminate specimens by Geenius HIV1/2 or WB. The Geenius HIV1/2 was performed in a total of 192 serum specimens (140 reactive and 52 nonreactive specimens by ARCHITECT HIV Ag/Ab Combo assay) that were prospectively collected from five institutions. We evaluated Bio-Rad Geenius HIV1/2 confirmation assay as a simple and reliable alternative to WB in the Korean population with low HIV prevalence. Recently updated recommendations for diagnosis of HIV infection suggest a new diagnostic algorithm including HIV-1/HIV-2 antibody differentiation immunoassay instead of western blot (WB) as a confirmatory testing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |